LU2458332611
© Globe Newswire
23.05.2025
ALVO
LISTED
ICE
Transactions of Managers and Closely Associated Persons
News Preview
Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition of 95,000 shares in Alvotech at ISK 1,260 per share, by Alvogen Lux Holdings S.ár.l., the second largest shareholder in Alvotech. The date of the tran...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.05.2025
ALVO
LISTED
ICE
Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm
News Preview
REYKJAVIK, ICELAND AND STOCKHOLM, SWEDEN (May 19, 2025) — Alvotech (NASDAQ: ALVO, the “Company”) has entered into agreement with DNB Carnegie Investment Bank AB (publ) (“DNB Carnegie”) regarding liquidity provider services to ensure liquidity in the Company’s Swedish Depository Receipts (“SDRs”), equity share equivalents, trading on Nasdaq Stockhol...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.05.2025
ALVO
LISTED
ICE
Alvotech Announces the Outcome of the Offering in Connection with the Company’s Listing on Nasdaq Stockholm
News Preview
Not to be released, published, distributed or circulated in any jurisdiction in which it would be unlawful to do so. This press release is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities....
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
16.05.2025
ALVO
LISTED
ICE
Transactions of Managers and Closely Associated Persons
News Preview
Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition of 19,988 shares in Alvotech at USD 10.18 per share, by Richard Davies, Deputy Chairman of the Board of Directors Alvotech. The transaction is dated M...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
13.05.2025
ALVO
LISTED
ICE
Leiðrétting: Viðskipti stjórnenda og tengdra aðila
News Preview
Í viðhengi er tilkynning um viðskipti stjórnenda og tengdra aðila sem lögð var inn til birtingar hjá fjármálaeftirliti Lúxemborgar, Luxembourg Commission de Surveillance du Secteur Financier (CSSF), um kaup Alvogen Lux Holdings S.ár.l. á 210,000 hlutum í Alvotech á genginu 1.277,38 krónur á hlut. Alvogen Lux Holdings er annar stærsti hluthafi Alvot...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.05.2025
ALVO
LISTED
ICE
Transactions of Managers and Closely Associated Persons
News Preview
Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition of 210,000 shares in Alvotech at ISK 1,277.38, by Alvogen Lux Holdings S.ár.l., the second largest shareholder in Alvotech. Alvogen Lux Holdings' larg...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.05.2025
ALVO
LISTED
ICE
Transactions of Managers and Closely Associated Persons
News Preview
Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition at the market opening of 320,000 shares in Alvotech at ISK 1,255 per share, by Robert Wessman, Chairman and CEO....
Themefolio
Profiler
Peergroup
© Globe Newswire
08.05.2025
ALVO
LISTED
ICE
Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm
News Preview
Not to be released, published, distributed or circulated in the United States or any other jurisdiction in which it would be unlawful to do so. This press release is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities....
Themefolio
Profiler
Peergroup
© Globe Newswire
07.05.2025
ALVO
LISTED
ICE
Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025
News Preview
REYKJAVIK, Iceland, May 07, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”) a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued a statement on the anticipated impact of potential tariffs on imported pharmaceuticals to the United States. Alvotech ex...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.05.2025
ALVO
LISTED
ICE
Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025
News Preview
Alvotech (NASDAQ: ALVO) (the “Company”) a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued a statement on the anticipated impact of potential tariffs on imported pharmaceuticals to the United States. Alvotech expects that potential U.S. tariffs on imported pharmaceut...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.05.2025
ALVO
LISTED
ICE
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
News Preview
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: ALVO) today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI™ (ustekinumab-aekn) injection as interchangeable with the reference biologic Stelara® (ustekinumab). As of April 30, 2025, SELARSDI is...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.03.2025
ALVO
LISTED
ICE
Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer
News Preview
Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of Dr. Balaji V. Prasad as Chief Strategy Officer....
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
27.03.2025
ALVO
LISTED
ICE
Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer
News Preview
REYKJAVIK, Iceland, March 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of Dr. Balaji V. Prasad as Chief Strategy Officer....
Themefolio
Profiler
Peergroup
© Globe Newswire
26.03.2025
ALVO
LISTED
ICE
Alvotech Reports Record Results for 2024 and Provides Business Update
News Preview
Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for full year 2024 and provided a summary of recent pipeline and corporate highlights. Management will conduct a business update conference call and live...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.03.2025
ALVO
LISTED
ICE
Alvotech Reports Record Results for 2024 and Provides Business Update
News Preview
REYKJAVIK, Iceland, March 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for full year 2024 and provided a summary of recent pipeline and corporate highlights. Managemen...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.03.2025
ALVO
LISTED
ICE
UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)
News Preview
REYKJAVIK, Iceland, PISCATAWAY, N.J. and LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.03.2025
ALVO
LISTED
ICE
UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)
News Preview
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and Advanz Pharma, a UK-headquartered global pharmaceutical company with a strategic focu...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.03.2025
ALVO
LISTED
ICE
Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production
News Preview
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the acquisition of Xbrane Biopharma AB’s (“Xbrane”) R&D operations and a biosimilar candidate (the “Acquisition”), further expanding Alvotech’s development capabilities, and establishi...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.03.2025
ALVO
LISTED
ICE
Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production
News Preview
Alvotech acquires all Xbrane's operations and Cimizia biosimilar candidate, further expanding development capabilities, considers listing on Swedish market...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.03.2025
ALVO
LISTED
ICE
Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida
News Preview
REYKJAVIK, Iceland, March 07, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in Barclays 27th Annual Global Healthcare Conference, which will be held in Miami, Florida on March 11-13, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
07.03.2025
ALVO
LISTED
ICE
Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida
News Preview
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in Barclays 27th Annual Global Healthcare Conference, which will be held in Miami, Florida on March 11-13, 2025. Robert Wessman, founder, chairman and CEO and members of...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.02.2025
ALVO
LISTED
ICE
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
News Preview
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: ALVO) today announced the availability of SELARSDI™ (ustekinumab-aekn) injection in the U.S., a biosimilar to Stelara® (ustekinumab), for the treatment of psoriatic arthritis, plaque psoriasis, Crohn’s disease, ulcerative colit...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.02.2025
ALVO
LISTED
ICE
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
News Preview
REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: ALVO) today announced the availability of SELARSDI™ (ustekinumab-aekn) injection in the U.S., a biosimilar to Stelara® (ustekinumab), for the treatmen...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.02.2025
ALVO
LISTED
ICE
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
News Preview
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologic...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.02.2025
ALVO
LISTED
ICE
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
News Preview
REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that t...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2025
ALVO
LISTED
ICE
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
News Preview
REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that t...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2025
ALVO
LISTED
ICE
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
News Preview
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Biologics...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.01.2025
ALVO
LISTED
ICE
Alvotech birtir fjárhagsdagatal fyrir árið 2025
News Preview
Stefnt er að því að birting árshluta- og ársuppgjörs Alvotech og aðalfundur félagsins fari fram sem hér segir á árinu 2025:...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.12.2024
ALVO
LISTED
ICE
Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024
News Preview
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its stock will be added to the Nasdaq Biotechnology Index (NASDAQ: NBI). The addition comes as a part of the annual reconstitution of the index. Alvotech’s inclusion in the NBI will b...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.12.2024
ALVO
LISTED
ICE
Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024
News Preview
REYKJAVIK, Iceland, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its stock will be added to the Nasdaq Biotechnology Index (NASDAQ: NBI). The addition comes as a part of the annual reconstitut...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.11.2024
ALVO
LISTED
ICE
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024
News Preview
REYKJAVIK, Iceland, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in Citi’s 2024 Global Healthcare Conference in Miami, Florida on December 4, 2024, and in Evercore’s HealthCONx Co...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.11.2024
ALVO
LISTED
ICE
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024
News Preview
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in Citi’s 2024 Global Healthcare Conference in Miami, Florida on December 4, 2024, and in Evercore’s HealthCONx Conference in Coral Gables, Florida on December 5, 2024. M...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.10.2024
ALVO
LISTED
ICE
Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024
News Preview
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies London Healthcare Conference, November 19-20, 2024. Members of the management team will host one-on-one meetings on both days. Alvotech will be presentin...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.10.2024
ALVO
LISTED
ICE
Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024
News Preview
REYKJAVIK, Iceland, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies London Healthcare Conference, November 19-20, 2024. Members of the management team will host one-...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.10.2024
ALVO
LISTED
ICE
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
News Preview
Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) in a new presentation, 130 mg/26 mL (5 mg/mL) solution in a single-dose vial for intravenous infusion. This approva...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.10.2024
ALVO
LISTED
ICE
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
News Preview
REYKJAVIK, Iceland & PARSIPPANY, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) in a new presentation, 130 mg/26 mL...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.10.2024
ALVO
LISTED
ICE
European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
News Preview
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT03, a proposed biosimilar candidate to Prolia® and Xgeva® (denosumab)....
Themefolio
Profiler
Peergroup
© Globe Newswire
10.10.2024
ALVO
LISTED
ICE
European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
News Preview
REYKJAVIK, Iceland, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT03, a proposed biosimilar candida...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.09.2024
ALVO
LISTED
ICE
Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®
News Preview
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a confirmatory patient study for AVT16, a biosimilar candidate to Entyvio® (vedolizumab). The objective of the study is to demonstrate comparative efficacy, safety, and im...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.09.2024
ALVO
LISTED
ICE
Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®
News Preview
REYKJAVIK, Iceland, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a confirmatory patient study for AVT16, a biosimilar candidate to Entyvio® (vedolizumab). The objective of the stu...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.08.2024
ALVO
LISTED
ICE
Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
News Preview
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announces its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York. Members of the management team will hold an in-person fireside chat on September 5, 2024, starting a...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.08.2024
ALVO
LISTED
ICE
Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
News Preview
REYKJAVIK, Iceland, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announces its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York. Members of the management team will hold an i...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.08.2024
ALVO
LISTED
ICE
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024
News Preview
REYKJAVIK, Iceland, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first six months of 2024 and provided a summary of recent corporate highlights....
Themefolio
Profiler
Peergroup
© Globe Newswire
15.08.2024
ALVO
LISTED
ICE
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024
News Preview
Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first six months of 2024 and provided a summary of recent corporate highlights....
Themefolio
Profiler
Peergroup
© Globe Newswire
15.08.2024
ALVO
LISTED
ICE
European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
News Preview
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency (...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.08.2024
ALVO
LISTED
ICE
European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
News Preview
REYKJAVIK, Iceland and LONDON, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medici...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.07.2024
ALVO
LISTED
ICE
Alvotech Announces Closing of Private Debt Financing
News Preview
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing of its previously announced senior secured first lien term loan facility (the “Facility”). The closing has allowed Alvotech to refinance outstanding debt obligations, reduce t...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.07.2024
ALVO
LISTED
ICE
Alvotech Announces Closing of Private Debt Financing
News Preview
REYKJAVIK, Iceland, July 11, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing of its previously announced senior secured first lien term loan facility (the “Facility”). The closing has allowed Alvot...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.07.2024
ALVO
LISTED
ICE
Alvotech Issues New Shares to Holders of Convertible Bonds
News Preview
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued new shares to holders of subordinated convertible bonds, originally issued by Alvotech on November 16, 2022, and December 20, 2022, with maturity on December 20, 2025 (the “Convertible Bonds”...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.07.2024
ALVO
LISTED
ICE
Alvotech Issues New Shares to Holders of Convertible Bonds
News Preview
REYKJAVIK, Iceland, July 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued new shares to holders of subordinated convertible bonds, originally issued by Alvotech on November 16, 2022, and December 20, 2022, wit...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.07.2024
ALVO
LISTED
ICE
Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
News Preview
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced certain preliminary, unaudited key financial information for the second quarter and six months ended June 30, 2024, as follows:...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.07.2024
ALVO
LISTED
ICE
Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
News Preview
REYKJAVIK, Iceland, July 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced certain preliminary, unaudited key financial information for the second quarter and six months ended June 30, 2024, as follows:...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.06.2024
ALVO
LISTED
ICE
Alvotech Receives Conversion Notices for Majority of Convertible Bonds
News Preview
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that holders of the majority of subordinated convertible bonds, originally issued by Alvotech on November 16, 2022, and December 20, 2022, respectively, with maturity on December 20, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.06.2024
ALVO
LISTED
ICE
Alvotech Receives Conversion Notices for Majority of Convertible Bonds
News Preview
REYKJAVIK, Iceland , June 26, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that holders of the majority of subordinated convertible bonds, originally issued by Alvotech on November 16, 2022, and December 20...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.06.2024
ALVO
LISTED
ICE
Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe
News Preview
REYKJAVIK, Iceland and LONDON, June 18, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medici...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.06.2024
ALVO
LISTED
ICE
Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe
News Preview
REYKJAVIK, ICELAND and LONDON, UK (June 18, 2024) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe,...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.06.2024
ALVO
LISTED
ICE
Alvotech and STADA add to Strategic Alliance through Denosumab Partnership
News Preview
Alvotech and STADA are strengthening their existing strategic alliance for high-quality, cost-effective biosimilars by extending their partnership to cover AVT03, a clinical-stage biosimilar candidate referencing the Prolia®/Xgeva® (denosumab) medicines for osteoporosis and cancer-related bone loss respectively....
Themefolio
Profiler
Peergroup
© Globe Newswire
11.06.2024
ALVO
LISTED
ICE
Alvotech and STADA add to strategic alliance through denosumab partnership
News Preview
REYKJAVIK, Iceland and BAD VILBEL, Germany, June 11, 2024 (GLOBE NEWSWIRE) -- Alvotech and STADA are strengthening their existing strategic alliance for high-quality, cost-effective biosimilars by extending their partnership to cover AVT03, a clinical-stage biosimilar candidate referencing the Prolia®/Xgeva® (denosumab) medicines for osteoporosis...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.06.2024
ALVO
LISTED
ICE
Alvotech Announces Strategic Refinancing Agreement
News Preview
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the successful arrangement of a strategic refinancing transaction. The financing, led by GoldenTree Asset Management, with participation from other institutional investors (collectively, t...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.06.2024
ALVO
LISTED
ICE
Alvotech Announces Strategic Refinancing Agreement
News Preview
REYKJAVIK, Iceland, June 07, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the successful arrangement of a strategic refinancing transaction. The financing, led by GoldenTree Asset Management, with participa...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
